Rocket Pharmaceuticals provided updates on its Danon Disease Program, reporting positive long-term safety and efficacy results from the Phase 1 RP-A501 study, including a 10% reduction in left ventricular mass index and sustained LAMP2 protein expression in patients. The company also noted plans to resume patient enrollment for the Phase 2 RP-L301 study in 2025.